A study conducted over 3 periods to look at the drug in the body

Study identifier:D2350C00007

ClinicalTrials.gov identifier:NCT01225939

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Open-label, Three-way Cross-over, Phase I Study in Healthy Subjects to Assess the Pharmacokinetics of AZD8329 after Single Doses of the Oral Solid Formulation and the Oral Solution

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD8329

Sex

Male

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Nov 2010

Primary Completion Date: 01 Dec 2010

Study Completion Date: 01 Dec 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2018 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

LONDON BRIDGE, United Kingdom

Arms	Assigned Interventions
Experimental: 1 Single Oral dose AZD8329 tablet (fasting)	Drug: AZD8329 tablet
Experimental: 2 Single Oral dose AZD8329 solution (fasting)	Drug: AZD8329 Solution
Experimental: 3 Single Oral dose AZD8329 tablet (Fed)	Drug: AZD8329 tablet

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1261&filename=CSR-D2350C00007.pdf
Download
CSR-D2350C00007.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

J Ritter

Quintiles Drug Research Unit at Guy's Hospital